(31.4% LGSC vs 64.5% BOT, p= <0.0001). 47.8% of LGSC-patients did not know the difference between LGSC and HGSC and 73.9% were not offered a hormone replacement therapy. BOT-patients estimate the aggressiveness (31.2% BOT vs. 52.2% LGSC) and the risk of recurrence (28.2% BOT vs. 44% LGSC) of their disease lower than LGSC-patients.

Conclusion
This study underlines the high need for more detailed explanation in this specific patient group with a greater focus on the underlying tumor biology and the corresponding course of disease and prognosis.